News
VOR
1.710
+1.79%
0.030
Weekly Report: what happened at VOR last week (0408-0412)?
Weekly Report · 4d ago
Buy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potential
TipRanks · 04/12 17:25
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
NASDAQ · 04/04 12:32
Weekly Report: what happened at VOR last week (0325-0329)?
Weekly Report · 04/01 09:22
Vor Bio to Participate in Upcoming Investor Conferences
Barchart · 04/01 07:00
PLAB, SMTC and WOOF are among after hour movers
On the Move PLAB, SMTC and WOOF are among after hour movers. Semtech Corporation, ANAB and ZNTL are among the biggest gainers in the biotech sector. PLAB and SMTC were among the largest losers in the pharmaceutical sector.
Seeking Alpha · 03/28 20:52
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Inotiv (NOTV) and Vericel (VCEL)
TipRanks · 03/26 12:50
Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)
TipRanks · 03/26 02:05
Weekly Report: what happened at VOR last week (0318-0322)?
Weekly Report · 03/25 09:23
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
3 analysts have recently maintained Buy ratings on Immatics, Vor Biopharma and Jazz Pharmaceuticals. The 3 stocks are in the Healthcare sector and are expected to make moves following their insider activities. 3 analysts just weighed in on  Immatics (IMTX – Research Report), Vor Bipharma (VOR – Research report) and Jazz pharmaceuticals with bullish sentiments.
TipRanks · 03/25 01:50
MASI, PLRX and CGC are among after hour movers
On the Move MASI, PLRX and CGC are among after hour movers. Airship AI Holdings and AISP are among the losers in the tech sector. The day's top 10 stocks include CAMP, CGNX and MLCO.
Seeking Alpha · 03/22 20:59
Vor Biopharma Price Target Maintained With a $12.00/Share by JMP Securities
Dow Jones · 03/22 17:23
JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
Benzinga · 03/22 17:13
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)
TipRanks · 03/22 04:30
Vor Biopharma Is Maintained at Buy by Stifel
Dow Jones · 03/21 13:49
Stifel Maintains Buy on Vor Biopharma, Lowers Price Target to $12
Benzinga · 03/21 13:39
Vor Biopharma Price Target Maintained With a $11.00/Share by Wedbush
Dow Jones · 03/21 13:20
Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Benzinga · 03/21 13:14
Vor Biopharma Price Target Cut to $15.00/Share From $17.00 by Oppenheimer
Dow Jones · 03/21 13:11
Oppenheimer Reiterates Outperform on Vor Biopharma, Lowers Price Target to $15
Benzinga · 03/21 13:02
More
Webull provides a variety of real-time VOR stock news. You can receive the latest news about Vor Biopharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VOR
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.